Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New name, same mission
July 2019
SHARING OPTIONS:

HALLE (SALLE), Germany—June 11 saw the official switch of Probiodrug AG’s company name to Vivoryon Therapeutics AG. The company will continue its focus on finding therapeutic solutions for Alzheimer’s disease, and PQ912, its lead molecule, will be moving into two clinical Phase 2b trials in Europe and the United States for the treatment of Alzheimer’s disease.
 
“Vivoryon, composed of ‘Vivid Memory On,’ expresses our strong commitment to develop a transformational therapeutic option for patients with Alzheimer’s disease against the backdrop of multiple late-stage industry disappointments. With our proprietary Glutaminyl cyclase inhibition platform, we are technology leaders in this field which has also opened up new opportunities to bring scientific excellence for the benefit of patients to other indications, as we currently see in immuno-oncology,” said Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.